FDA Approves Antibiotic Treatment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Approves Antibiotic Treatment


FDA has approved Cubist Pharmaceuticals’ Sivextro (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). Sivextro addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which has been categorized by the US Centers for Disease Control and Prevention (CDC) as a serious public health threat.

On March 31, 2014 an FDA Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Sivextro. In the unanimous decision, the AIDAC found that substantial evidence of the safety and effectiveness of Sivextro for the treatment of ABSSSI was provided.

Sivextro is administered once daily for a short, six-day course of therapy. Sivextro is a oxazolidinone with in vitro activity against clinically significant susceptible Gram-positive pathogens including MRSA and is now approved in both intravenous and oral formulations.

Sivextro is one of the first medicines approved in the US that FDA designated as a Qualified Infectious Disease Product (QIDP) for its indication, ABSSSI, according to the Generating Antibiotic Incentives Now Act of 2012. The QIDP designation qualifies Sivextro for certain incentives related to the development of new antibiotics, including a five-year extension of Hatch-Waxman exclusivity.

"MRSA is still problematic in the US and is responsible for the deaths of more than 11,000 Americans each year," said Ralph Corey, MD, Professor of Medicine and Infectious Disease, Duke Clinical Research Institute and Duke University Medical Center, in the press release. "Not every antibiotic will work for every patient and more drug options are an imperative."

Source: Cubist

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here